| Pharmaceuticals | Generic oncology, cardiology, diabetology, infectious disease drugs, and export formulations. | Strong R&D, backward integrated API manufacturing, robust US FDA approvals, exclusive licenses, and diversified global footprint. | B2B and B2C including hospitals, pharmacies, healthcare providers primarily in USA, India, and global markets. | Complex oncology generics and antiviral therapies have highest margins. | 2666 | 98 | Sales of formulations, licensing, and profit-sharing arrangements. | Direct sales with mix of fixed contracts, licensing fees, and variable pricing in generic markets. | FDA approvals,Para IV filings, strategic launches in oncology and antivirals, expansion in domestic and export markets. | Veenat, Hepcinat, Velpanat, Xpreza, Pazonat, Cazanat, Tipanat |
| Agrochemicals | Broad-spectrum insecticides including Chlorantraniliprole formulations and combination products. | Innovative formulations, brand recognition, and agronomic expertise supporting market penetration. | B2B focus targeting agricultural sector and distributors within India and selected overseas markets. | Specialty insecticide formulations and combination products. | 41 | 2 | Product sales in domestic and export agrochemical markets. | Product sales through distribution network and field agents. | New product launches, increasing acreage coverage, emphasis on crop phenology and export exploration. | NATGEN, NATERRA, NATVOL, NATLIGO |
